Talzenna (talazoparib) — United Healthcare
metastatic castration-resistant prostate cancer
Initial criteria
- Diagnosis of metastatic castration-resistant prostate cancer
- Presence of homologous recombination repair (HRR) gene mutations
- Used in combination with Xtandi (enzalutamide)
- One of the following: (a) Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)] OR (b) Patient has had bilateral orchiectomy
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Talzenna therapy
Approval duration
12 months